Friday 28th November 2025

13:45  Welcome and introduction (R. Stahel, S. Peters)

Early NSCLC (S. Peters)

14:00  Current recommendations for pathological workup and reflex testing (L. Bubendorf, Basel)

14:30  Role of immunotherapy in surgical stage II-III NSCLC (S. Peters, Lausanne)

15:00   Role of immunotherapy in unresectable stage III NSCLC (M. Pless, Winterthur)

15:30  Coffee break

SCLC (M. Pless)

16:00  Role of RT in SCLC (J. Willmann, Zürich)

16:30  Developments in frontline ED SCLC (M. Früh, St. Gallen)

17:00  Developments in late lines ED SCLC (M. Perol, Lyon)

Mesothelioma

17:30   All you need to know about mesothelioma (P. Baas, Leiden)

18:00   2 cases

18:30   Adjourn

Saturday 29th November 2025

Advanced AGA negative NSCLC (L. Mauti)

08:00  Development of ADCs in thoracic malignancies (D. Planchard, Paris)

08:30   Standards of care and prospects for IO in advance NSCLC (S. Rothschild, Baden)

09:00   other developments in precision oncology for advanced NSCLC (O. Gautschi, Luzern)

09:30   2 cases

10:00  Coffee break

Pulmonology (O. Gautschi)

10:30  Any progress in screening for NSCLC in 2024? (C. Von Garnier, Lausanne)

10:50  Research projects and vision of SAKK lung group 2026 (A. Curioni, Fribourg)

Oncogene Addiction (S. Peters)

11:10  Targeting EGFR (A. Passaro, Milano)

11:30  Targeting ALK (L. Mauti, Winterthur)

11:50  Other selected developments in targeted therapies (A. Addeo, Genève)

12:10  Result of the best case presentation / Wrap up (R. Stahel, Zürich)

12:15  End